A randomized phase II study of sorafenib/gemcitabine or sorafenih/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: Treatment rationale and protocol dynamics

Clinical Lung Cancer

Volumn 8, Issue 6, 2007, Pages 396-398

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Mongillo, Floriana ^b   Bareschino, Maria ^b   Maione, Paolo ^a   Ciardiello, Fortunato ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Vascular endothelial growth factor receptor

Indexed keywords

BIOLOGICAL MARKER; ERLOTINIB; GEMCITABINE; SORAFENIB;

ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DYNAMICS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 34250324694     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2007.n.023     Document Type: Article

References (17)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353.
3. Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non small cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004; 15:419-426.
4. Gridelli C, Maione P, Rossi A, et al. Chemotherapy of stage I to III non-small cell lung cancer in the elderly patients. American Society of Clinical Oncology 2005 Educational Book; Alexandria, VA: ASCO; 2005:611-617.
5. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly parients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-372.
6. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21:1383-1389.
7. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067.
8. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
9. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non small cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005; 23:3125-3137.
10. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-766.
11. Jackman DM, Yeap B, Lucca J, et al. Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): an analysis quality of life and symptom response. J Clin Oncol 2006; 24(18 suppl):406s (Absrracr #7168).
12. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
13. Carter CA, Chen C, Brink C, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007; 59:183-195.
14. Gatzemeier U, Blumenschein G, Fosella F. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006; 24(18 suppl):673s (Abstract #7002).
15. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
16. Duran I, Hotte S, Hirte H, et al. Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors. Eur J Cancer 2006; 4(suppl ???):167.
17. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006; 12:144-151.